A Philadelphia judge has ruled that the scientific methodologies used by key plaintiffs’ expert witnesses in the 1,500 cases pending in the hormone replacement therapy mass tort litigation are not novel and are admissible in court.

Philadelphia Common Pleas Judge Sandra Mazer Moss ruled from the bench against a defense motion Wednesday. Moss said she was ruling from the bench because the experts are slated to testify in trials starting today and Monday in which plaintiffs allege their breast cancer was caused by drugs manufactured by Pfizer or other defendants.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]